TransMedics Group Inc
Uždarymo kaina
SektoriusSveikatos priežiūra
73.67 -2.19
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
72.59
Max
75.5
Pajamos | -98M 7.3M |
|---|---|
Pardavimai | 13M 174M |
P/E Sektoriaus vid. | 17.279 49.712 |
Pelnas, tenkantis vienai akcijai | 0.3 |
Pelno marža | 4.206 |
Darbuotojai | 898 |
EBITDA | -4.9M 28M |
Rekomendacijos | Pirkti |
|---|---|
12 mėnesių prognozė | +59.25% upside |
Kitas uždarbis | 2026-07-29 |
|---|
Rinkos kapitalizacija | -744M 2.6B |
|---|---|
Ankstesnė atidarymo kaina | 75.86 |
Ankstesnė uždarymo kaina | 73.67 |
Naujienos nuotaikos
By Acuity
50%
50%
128 / 342 reitingas Healthcare
TransMedics Group Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.